Post-treatment CIN: Randomised clinical trial using hrHPV testing for prediction of residual/recurrent disease

International Journal of Cancer

Volumn 124, Issue 4, 2009, Pages 889-895

  Bais, Aagje G ^a   Eijkemans, Marinus J C ^a   Rebolj, Mateja ^a   Snijders, Peter J F ^b   Verheijen, René H M ^b   Van Ballegooijen, Marjolein ^a   Meijer, Chris J L M ^b   Helmerhorst, Theo J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cervical intraepithelial neoplasia; Hhuman papillomavirus; RC I; Residual recurrent CIN

Indexed keywords

ADULT; ARTICLE; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; NETHERLANDS; OUTPATIENT DEPARTMENT; POPULATION RISK; POST HOC ANALYSIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; WART VIRUS; GENETICS; METHODOLOGY; MIDDLE AGED; PAPILLOMA VIRUS; PATHOLOGY; RISK; TIME; UTERINE CERVIX; VAGINA SMEAR; VIROLOGY; VIRUS INFECTION;

VIRUS DNA;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RECURRENCE; RISK; TIME FACTORS; TREATMENT OUTCOME; VAGINAL SMEARS;

EID: 58149458147     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23824     Document Type: Article

References (36)

1. Bulk S, van Kemenade FJ, Rozendaal L, Meijer CJ. The Dutch CTSOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004; 57:388-93.
2. Bigrigg A, Haffenden DK, Sheehan AC, Codling BW, Read MD. Efficacy and safety of large-loop excision of the transformation zone. Lancet 1994;343:32-4.
3. Jain S, Tseng CJ, Horng SG, Soongy K, Pao CC. Negative predictive value of human papillomavirus test following conization of the cervix uteri. Gynaecol Oncol 2001;82:177-80.
4. Chua KL, Hjerpe A. Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri. Gvnaecol Oncol 1997;66:108-13.
5. Benedet JL, Miller DM, Nickerson KG. Results of conservative management of cervical intraepithelial neoplasia. Obstet Gvnaecol 1992;79:105-10.
6. Bistoletti P, Zellbi A, Moreno-Lopez J, Hjerpe A. Genital papillomavirus infection after treatment for cervical intraepithelial neoplasia (CIN) III. Cancer 1988;62:2056-9.
7. Mitchell MF, Tortolero-Luna G, Cook E, Whittaker L, Rhodes-Morris H, Silva E. A randomised clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynaecol 1998;92:737-44.
8. Bollen LJM, Tjong-A-Hung SP, van der Velden J, Mol BW, ten Kate FW, ter Schegget J, Bleker OP. Prediction of recurrent and residual cervical dysplasia by human papillomavirus detection among patients with abnormal cytology. Gynecol Oncol 1999;72:199-201.
9. Nagai Y, Maehama T, Asato T, Kanazawa K. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence? Gynaecol Oncol 2000;79:294-9.
10. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
11. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
12. Nobbenhuis MAE, Walboomers JMM, Helmerhorst ThJM, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ. Relation of human papillomavirus status to cervical lesions and consequences for cervical-screening: a prospective study. Lancet 1999;354:20-5.
13. Nobbenhuis MA, Meijer CJ, van den Brule AJ. Rozendaal L, Voorhorst FJ, Risse EK, Verheijen RH, Helmerhorst TJ. Addition of high-risk HPV testing improves the current guidelines on follow up after treatment for cervical intraepithelial neoplasia. Br J Cancer 2001; 84:796-801.
14. Rozendaal L, Westerga J, van der Linden JC, Walboomers JM, Voorhorst FJ, Risse EK, Boon ME, Meijer CJ. PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes. J Clin Pathol 2000;53:606-11.
15. Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, Ransley JE, Fetterman BJ, Hartinger JS, Mcintosh KM, Pawlick GF, Hiatt RA. Identifying women with cervical neoplasia: using human papillomavirus testing for equivocal Papanicolaou results. J AMA 1999;281:1605-9.
16. Meijer CJ, Helmerhorst TJ, Rozendaal L, van der Linden JC, Voorhorst FJ, Walboomers JM. HPV typing and testing in gynaecological pathology: has the time come? Histopathology 1998; 33:83-6.
17. Eifgren K, Bistoletti P, Dillner L, Walboomers JM, Meijer CJ, Diliner J. Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Am J Obstet Gynecol 1996;174:937-42.
18. Zielinski GD, Rozendaal L, Voorhorst FJ, Berkhof J, Snijders PJ, Risse EJ, Runsink AP, de Sehipper FA, Meijer CJ. HPV testing can reduce the number of follow-up visits post-treatment of cervical intraepithelial neoplasia grade 3. Gynecol Oncol 2003;91:67-73.
19. Zielinski GD, Bais AG, Helmerhorst ThJ, Verheijen RH, de Sehipper FA, Snijders PJ, Voorhorst FJ, van Kemenade FJ, Rozendaal L, Meijer CJ. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv 2004;59:543-53.
20. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Diliner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women for high-grade CIN: an update of pooled evidence. Gynecol Oncol 2005;S7-S11.
21. Paraskevaidis E, Koliopoulos G, Alamanos Y, Malamou-Mitsi V, Lolis ED, Kitchener HC. Human papillomavirus testing and the outcome of treatment for cervical intraepithelial neoplasia. Obstet Gynecol 2001:98(5, Part 1): 833-6.
22. Paraskevaidis E, Arbyn M, Sotiriadis A, Diakomanolis E, MartinHirsch P, Koliopoulos G, Makrydimas G, Tofoski J, Roukos DH. The role of HPV-DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev 2004;30:205-11.
23. van den Brule ACJ, Pol R, Fransen-Dahlmeijer N, Schouls LM, Meijer CJ, Snijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papilloma virus genotypes, J Clin Microbiol 2002;40:779-87.
24. Bulkmans NWJ, Rozendaal L, Snijders PJF, Voorhorst FJ, Boeke AJ, Zandwijken GR, van Kemenade FJ, Verheijen RH, van Groningen K, Boon ME, Keuning HJ, van Ballegooijen M, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening; design, methods and baseline data of 44,102 women. Int J Cancer 2004; 110:94-101.
25. Hanselaar AG. Criteria for organized cervical screening programs, Special emphasis on The Netherlands program. Acta Cytol 2002:46:619-29.
26. Coupé VMH, Berkhof J, Verheijen RHM, Meijer CJLM. Cost-effectiveness evaluation of follow-up strategies with high-risk HPV testing after treatment for high-grade cervical intraepithelial neoplasia. BJOG 2007;1114:416-24.
27. Rebolj M, Bais AG, van Ballegooijen M, Boer R, Meerding WJ, Helmerhorst TJ, Habbema JD. Human papillomavirus triage of women with persistent borderline or mildly dyskaryotic smears: comparison of costs and side effects of three alternative strategies. Int J Cancer 2007:121:1529-35.
28. Berkhof J, de Bruijne MC, Zielinski GD, Bulkmans NW, Rozendaal L, Snijders PJ, Verheijen RH, Meijer CJ. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dvskarvosis. Int J Cancer 2006;118:1759-68.
29. Costa S, De Simone P, Venturoli S, Cricca M, Zerbini ML, Musiani M, Terzano P, Santini D, Cristiani P, Syrjanen S, Syrjanen K. Factors predicting human papillomavirus clearance in cervical neoplasia lesions treated by conization. Gynecol Oncol 2003;90:358-65.
30. Alonso I, Torne A, Puig-Tintore LM, Esleve R, Quinto L, Campo E, Pahisa J, Ordi J. Pre-and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. Gynecol Oncol 2006;103:631-6.
31. Remmink AJ, Walboomers JMM, Helmerhorst ThJM, Voorhorst FJ, Rozendaal L, Risse EK, Meijer CJ, Kenemans P. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995;6l:306-l1.
32. Oortmarssen GJv, Habbema JD. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer 1991;64:559-65.
33. Houfflin Debarge VH, Collinet P, Vinatier D, Ego A, Dewilde A, Boman F, Leroy JL. Value of HPV testing after conization by LETZ excision for high-grade squamous intraepithelial lesions. Gynecol Oncol 2003;90:587-92.
34. Gok M, Coupe VHM, Berkhof J, Verheijen RH, Helmerhorst TJ, Hogewoning CJ, Snijders PJ, Meijer CJ. HPV 16 and increased risk of recurrence after treatment for CIN. Gynecol Oncol 2007;104:273-5.
35. Van Ham M, van Hamount D, Bekkers RLM, Bulten J, Melchers WJG, Massuger LFAG. High-risk HPV presence in cervical specimens after a large loop excision of the cervical transformation zone: significance of newly detected hr-HPV genotypes. J Med Virol 2007:79:314-319.
36. Kreimer AR, Guido RS, Solomon D, Schiffraan M, Wacholder S, Jeronimo J, Wheeler CM, Castle PE. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev 2006;15:908-14.